However, anti-VEGF therapy and PD-1/PD-L1 inhibitors presented with synergistic effect in treating MSS-CRC in recent years, with an ORR ranging from 7.1% to 60% (18–20). The gene discussed is CD274; the disease is colorectal carcinoma.